靶向抗肿瘤前药系统的研究进展

世界上约10％被批准的药物可归类为前药。前药是一类在体外无生物活性或低生物活性，可在体内经生物转化释放出原药而发挥药物毒作用的物质。前药设计主要是用来改善药物的物化、生物学和药代动力学性质。本文主要综述前药在肿瘤靶向治疗理念中的研究进展，主要包括抗体导向的酶前药疗法（antibodydirectedenzymeprodrugtherapy，ADEPT）和基因导向的酶前药疗法（genedirectedenzymeprodrugtherapy，GDEPT）等。

Study Progress of Targeting Anticancer Prodrug System

About 10% of the approved drugs worldwide can be classified as prodrugs. Prodrug, a kind of substance with no biological activities or inactive biological activities in vitro, can release active compound and become toxicity sub- stance through biotransformation in vivo. Prodrug design is primarily used for improving the properties of physic - chemis- try, biology and pharmacokinetics. This paper summarizes the research progress of prodrugs in treating targeting tumor, in- cluding antibody directed enzyme prodrug therapy （ADEPT） and gene directed enzyme prodrug therapy （GDEPT）.